For the year ending 2025-12-31, XOMA had $27,294K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Income and revenues | 52,149 |
| Business development and deal related costs | 6,654 |
| Research and development expenses | 1,712 |
| Depreciation of property and equipment | 11 |
| Other general and administrative expenses | 29,427 |
| Amortization of intangible assets | 2,961 |
| Gains on acquisitions | 21,224 |
| Change in fair value of derivatives related to castle creek | 93 |
| Interest expense | 13,031 |
| Other income, net | 12,145 |
| Income tax (expense) benefit | 103 |
| Net income (loss) | 31,712 |
| Adjustment for income from eir method purchased receivables | -5,925 |
| Stock-based compensation expense | 9,273 |
| Gains on acquisitions | 21,224 |
| Gain on sale of equity securities | 3,663 |
| U.s. federal statutory tax rate | 6,681 |
| Foreign tax effects | 103 |
| Changes in valuation allowances | -2,538 |
| Stock based compensation | -584 |
| Nondeductible executive compensation | 735 |
| Bargain purchase gain | 4,457 |
| Other permanent differences | 163 |
| Income tax expense (benefit) | 103 |
| Common stock contribution to 401 | 141 |
| Amortization of intangible assets | 2,961 |
| Depreciation | 11 |
| Accretion of long-term debt discount and debt issuance costs | 1,385 |
| Non-cash lease expense | -64 |
| Change in fair value of equity securities | 90 |
| Change in fair value of available-for-sale debt securities classified as cash equivalents | -20 |
| Change in fair value of derivatives | 93 |
| Cvr liability working capital adjustment | 394 |
| Trade and other receivables, net | 2,426 |
| Prepaid expenses and other assets | -3,839 |
| Accounts payable and accrued liabilities | -10,597 |
| Operating lease liabilities | -876 |
| Unearned revenue recognized under units-of-revenue method | -1,310 |
| Net cash provided by (used in) operating activities | 2,871 |
| Net cash acquired in acquisition-Turnstone Biologics Corp | 3,850 |
| Net cash and restricted cash acquired in acquisition-Hillevax Inc | 46,384 |
| Net cash and restricted cash acquired in acquisition-Lava Therapeutics Nv | 15,263 |
| Net cash and restricted cash acquired in acquisition-Mural Oncology Plc | 4,464 |
| Payments of consideration under rpas, aaas, and cppas | 8,000 |
| Receipts under rpas, aaas, and cppas | 3,300 |
| Payment for bioinvent contract-based intangible asset | 20,725 |
| Payment of contingent consideration related to kinnate ip asset | 550 |
| Purchase of equity securities | 99 |
| Sale of equity securities | 6,999 |
| Payment to issue short-term loan to xeno | 5,877 |
| Receipt from short-term loan repayment by xeno | 5,877 |
| Net cash provided by (used in) investing activities | 50,886 |
| Proceeds from issuance of common stock | 323 |
| Proceeds from issuance of preferred stock | 4,019 |
| Payments of preferred and common stock issuance and financing costs | 672 |
| Principal payments - debt | 10,598 |
| Debt issuance costs and loan fees paid in connection with long-term debt | 80 |
| Payment of preferred stock dividends | 5,472 |
| Repurchases of common stock | 16,043 |
| Proceeds from exercise of options and other share-based compensation | 5,046 |
| Taxes paid related to net share settlement of equity awards | 2,986 |
| Net cash used in financing activities | -26,463 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 27,294 |
| Cash, cash equivalents, and restricted cash as of the beginning of the period | 106,416 |
| Cash, cash equivalents, and restricted cash as of the end of the period | 133,710 |
XOMA Royalty Corp (XOMA)
XOMA Royalty Corp (XOMA)